<DOC>
	<DOCNO>NCT01018602</DOCNO>
	<brief_summary>The aim study prove efficacy oral intake vildagliptin daily dose 100 mg scope development type 2 diabetes woman insulin dependent gestational diabetes last pregnancy longer 9 month birth . In randomized , placebo-controlled , double-blinded clinical phase II study , 140 participant age 18 year old insulin dependent gestational diabetes last pregnancy include treated vildagliptin placebo 24 month , follow 12 month observation period . Exclusion criterion pregnancy lactation well clinical overt diabetes islet autoimmunity . The null hypothesis significant difference diabetes incidence ( accord ADA criterion 1997 ) group . Primary endpoint clinical manifestation diabetes , secondary endpoint include improvement beta cell function ( evaluable C-peptide measurement ) insulin sensitivity treatment vildagliptin .</brief_summary>
	<brief_title>PINGUIN ( Postpartum Intervention Women With Gestational Diabetes Using Insulin )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>woman insulindependent gestational diabetes last pregnancy &lt; 9 month delivery age 18 year old contraception intervention period ( least 24 month ) pregnancy lactation GADA IA2A positivity clinical overt diabetes</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>